David Dreman

Last Update: 02-14-2017

Number of Stocks: 450
Number of New Stocks: 51

Total Value: $178 Mil
Q/Q Turnover: 32%

Countries: USA
Details: Top Buys | Top Sales | Top Holdings  Embed:

David Dreman' s Profile & Performance

Profile

David Dreman is the founder and Chairman of Dreman Value Management, LLC and also serves as the firm's Chief Investment Officer. A regular columnist for Forbes for 25 years, Mr. Dreman's recent best-selling book, "Contrarian Investment Strategies: The Next Generation?" was published in the spring of 1998.

Web Page:http://www.dreman.com/news/

Investing Philosophy

The Contrarian and the value guru, Dreman's investment philosophy is based on low P/E approach to stock selection. The philosophy at Dreman Value Management: "We invest in undervalued companies that exhibit strong fundamentals, above-market dividend yields and historic earnings growth, which our analysis indicates will persist. Our strategy is to own strong, fundamentally sound companies and to avoid speculative stocks or potential bankruptcies." They believe that the markets are not perfectly efficient, and that behavioral psychology influences investor actions and reactions.

Total Holding History

Performance of Large Cap Value Composite

YearReturn (%)S&P500 (%)Excess Gain (%)
20147.5713.69-6.1
201333.1432.390.8
201212.3316-3.7
3-Year Cumulative60.9 (17.2%/year)74.6 (20.4%/year)-13.7 (-3.2%/year)
2011-8.032.11-10.1
201014.7215.06-0.3
5-Year Cumulative69.7 (11.2%/year)105.1 (15.5%/year)-35.4 (-4.3%/year)
200926.9126.460.5
2008-44.97-37-8.0
2007-1.375.49-6.9
200617.515.791.7
20057.714.912.8
10-Year Cumulative48 (4%/year)109.4 (7.7%/year)-61.4 (-3.7%/year)
200412.6510.881.8

Top Ranked Articles

Undervalued Financial Services Companies Among Top Buys Low prices relative to the fair value increase value potential
Among companies trading on the New York Stock Exchange and Nasdaq, financial services companies currently trade below their fair values. Read more...
Value Investors Avoided Deutsche Bank and 2 Other European Financials They were the least-held in the sector
Value gurus mostly exited Deutsche Bank (NYSE:DB) before its stock tumbled this month on news it might have to pay a large fine related to the financial crisis. While many maintain positions in other European banks as fear weighs on stocks in the sector, they are avoiding two almost as much as Deutsche Bank: Banco Santander SA (NYSE:SAN) and Lloyds Banking Group PLC (NYSE:LYG). Read more...
Divestitures Dominate Dreman's Top 10 Transactions in 2nd Quarter Financial services and energy companies account for most of transactions
Seven of David Dreman (Trades, Portfolio)’s top 10 transactions in the second quarter were exits from positions that have been in Dreman Value Management’s portfolio for most of the past six years. Dreman is the founder and chairman of the investment company. Read more...
Gilead Sciences Must Answer to Investors After a Disappointing 2016 Investors are concerned about the company's lack of a plan for the future
Gilead Sciences Inc. (NASDAQ:GILD) delivered a poor performance last year. The stock lost over 24% in 2016, caused by a drop in sales of products that treat hepatitis C. According to Ben Levinsohn in a Barron's article, the decline was also attributed to the company’s lack of a plan for the future. Read more...
Insider Invests in Spectra Energy Partners CEO and president bought 8,529 shares
Gregory Ebel (Insider Trades), CEO and president of Spectra Energy Partners (NYSE:SEP), purchased 8,529 shares of the company on Nov. 7. The average price per share was $41.67 for a total transaction of $355,403. Spectra Energy Partners, a master limited partnership in the United States, connects natural gas and crude oil supply to the market. The company has a market cap of $12.73 billion. Read more...
» More David Dreman Articles

Commentaries and Stories

  • Currently 4.00/5

Rating: 4.0/5 (1 vote)

Is Williams-Sonoma a Better Bargain Than Ever? The retailer's investment prospects after its recent price decline Joel Greenblatt,David Dreman,Ray Dalio,Ken Fisher - Is Williams-Sonoma A Better Bargain Than Ever?
(Published by Nicholas McCullum on March 19) More...

DIVIDENDS, RETAIL


  • Currently 0.00/5

Rating: 0.0/5 (0 votes)

AbbVie Regimen Recommended for HCV Infection VIEKIRAX + EXVIERA shows high cure rates in GT1b HCV patients David Dreman,Joel Greenblatt,Ken Fisher,Mario Gabe - AbbVie Regimen Recommended For HCV Infection
AbbVie Inc. (NYSE:ABBV) communicated through the PRNewswire Monday that it received a positive feedback from the European Committee for Medicinal Products for Human Use (CHMP) about the possibility of using VIEKIRAX plus EXVIERA in a combined therapy of eight weeks to treat chronically genotype 1b HCV-infected adult patients. More...

  • Currently 0.00/5

Rating: 0.0/5 (0 votes)

AbbVie Declares Quarterly Dividend Analysts forecast increases in 2017 EPS and sales David Dreman, Joel Greenblatt, Mario Gabelli, Ken  - AbbVie Declares Quarterly Dividend
AbbVie Inc. (NYSE:ABBV) annouced a quarterly dividend of 64 cents per share on Feb. 16. More...

  • Currently 0.00/5

Rating: 0.0/5 (0 votes)

AbbVie's Hepatitic C Treatment Under Accelerated Review by EMA Treatment is still waiting for FDA approval David Dreman,Joel Greenblatt - AbbVie's Hepatitic C Treatment Under Accelerated Review By EMA
 AbbVie Inc. (NYSE:ABBV) announced Tuesday through the PR Newswire that the European Medicines Agency has validated its marketing authorization application. The company's application seeks permission to rapidly bring its “investigational, pan-genotypic regimen of glecaprevir (ABT-493)/pibrentasvir (ABT-530) (G/P)” to the market. More...

  • Currently 0.00/5

Rating: 0.0/5 (0 votes)

Goldcorp Sells Cerro Blanco to Bluestone Resources Miner sells interest for $18 million David Dreman,First Eagle Investment - Goldcorp Sells Cerro Blanco To Bluestone Resources
Goldcorp Inc. (NYSE:GG) announced Wednesday it agreed to sell its 100% interest in the Cerro Blanco gold-silver project in Guatemala to Bluestone Resources Inc. (TSXV:BSR). More...

  • Currently 0.00/5

Rating: 0.0/5 (0 votes)

HollyFrontier Upgraded by Deutsche Bank The firm set a target price of $38 David Dreman,Keeley Asset Management Corp - HollyFrontier Upgraded By Deutsche Bank
HollyFrontier Corp. (NYSE:HFC) has been upgraded by Deutsche Bank, which now suggests buying shares of the refining company. Prior to this rating, Deutsche Bank released a hold on shares of HollyFrontier. More...

  • Currently 0.00/5

Rating: 0.0/5 (0 votes)

Desjardins Capital Markets Picks Goldcorp for 2017 Company's outlook on output and costs will be appealing for many years First Eagle Investment,David Dreman,Mario Gabelli - Desjardins Capital Markets Picks Goldcorp For 2017
Goldcorp Inc. (NYSE:GG) appears at the top of the list of Desjardins Capital Markets for the large-cap stocks that the firm recommends buying for 2017. The firm says the company “will be able to illustrate an attractive multiyear guidance outlook on both production and costs,” as reported by the Financial Post. More...

  • Currently 0.00/5

Rating: 0.0/5 (0 votes)

5 Best Contrarian Stocks for Your Portfolio Here's a breakdown of the 5 top stocks based on the Contrarian Approach David Dreman - 5 Best Contrarian Stocks For Your Portfolio
(This article appeared first on The Stock Market Blueprint Blog.) More...

VALUE STOCKS, QUICK PICKS, LONG, CONTRARIAN STOCKS, DAVID DREMAN


  • Currently 0.00/5

Rating: 0.0/5 (0 votes)

Gilead Sciences Must Answer to Investors After a Disappointing 2016 Investors are concerned about the company's lack of a plan for the future David Dreman,John Rogers - Gilead Sciences Must Answer To Investors After A Disappointing 2016
Gilead Sciences Inc. (NASDAQ:GILD) delivered a poor performance last year. The stock lost over 24% in 2016, caused by a drop in sales of products that treat hepatitis C. According to Ben Levinsohn in a Barron's article, the decline was also attributed to the company’s lack of a plan for the future. More...

  • Currently 0.00/5

Rating: 0.0/5 (0 votes)

Mean Reversion and the Bell Curve The pressure to outperform all the time leads stock pickers to constantly seek mean reversion trades David Dreman,Warren Buffett - Mean Reversion And The Bell Curve
Over a three-year time period, stock prices tend to mean revert. This has spawned numerous investment approaches that try to squeeze capital gains out of those reversions. Classic deep value investing, as popularized by Benjamin Graham at Columbia Business School, taught that you would succeed by buying 50-cent dollars and selling them when and if they reverted to the mean. The "Dogs of the Dow" strategy of buying the 10 highest-yielding Dow stocks was born out of mean reversion. More...

MEAN REVERSION, VALUE INVESTING, WARREN BUFFETT


  • Currently 0.00/5

Rating: 0.0/5 (0 votes)

David Dreman Gains, Increases Multiple Positions in 3rd Quarter The guru heavily invested in 2 holdings David Dreman - David Dreman Gains, Increases Multiple Positions In 3rd Quarter
David Dreman (Trades, Portfolio) is the founder and chairman of Dreman Value Management LLC and also serves as the firm's chief investment officer. During the third quarter, the guru’s largest buys were the following: More...

  • Currently 0.00/5

Rating: 0.0/5 (0 votes)

Goldcorp Downgraded by BMO Capital The firm downgraded the miner to market perform with a target price of $15 David Dreman,First Eagle Investment - Goldcorp Downgraded By BMO Capital
Goldcorp Inc. (NYSE:GG) has been downgraded by BMO Capital Markets from outperform to market perform with a new target price of $15 per share, down 34.8% from the previous target price of $23 per share. More...

  • Currently 0.00/5

Rating: 0.0/5 (0 votes)

AbbVie Files for Approval of Hepatitis C Treatment in the US The application is backed by relevant results and the company will apply in Europe in the first quarter of 2017 David Dreman,Joel Greenblatt - AbbVie Files For Approval Of Hepatitis C Treatment In The US
AbbVie (NYSE:ABBV) announced today through PRNewswire that it has filed a New Drug Application (NDA) with the U.S. Food and Drug Administration for its “investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P).” More...

  • Currently 0.00/5

Rating: 0.0/5 (0 votes)

David Dreman Sells St. Jude Medical, Ford Contrarian investor nearly closes stake in medical company David Dreman - David Dreman Sells St. Jude Medical, Ford
David Dreman (Trades, Portfolio) is the founder and chairman of Dreman Value Management and also serves as the firm's CIO. The guru made the following sales during the third quarter. More...

  • Currently 0.00/5

Rating: 0.0/5 (0 votes)

Goldcorp, Eldorado Gold Announce Management Changes Mining companies appoint new leadership Charles Brandes,David Dreman - Goldcorp, Eldorado Gold Announce Management Changes
Eldorado Gold Corp. (NYSE:EGO) and Goldcorp Inc.(NYSE:GG) announced changes in their top management today. More...

  • Currently 0.00/5

Rating: 0.0/5 (0 votes)

Newmont May Book up to $1.2 Billion to Shut Down Peru Mine The largest gold producer in the US estimates higher than initially expected additional costs David Dreman,Donald Smith,Mario Gabelli,First Eagl - Newmont May Book Up To $1.2 Billion To Shut Down Peru Mine
Newmont Mining Corp. (NYSE:NEM) says that it may book approximately $1 billion or even $1.2 billion noncash impairment charge in the last quarter due to a higher than initially assessed value of “the asset retirement obligation at the mine of between $400 million and $500 million in the fourth quarter” for the shutting down of Yanacocha, the Peruvian mine, as reported Wednesday by Reuters.com. More...

  • Currently 0.00/5

Rating: 0.0/5 (0 votes)

Goldcorp to Sell 2 Mexican Mines The Canadian miner will use the proceeds to reduce debt and develop other projects David Dreman,First Eagle Investment - Goldcorp To Sell 2 Mexican Mines
According to news reported by Bloomberg yesterday, the Bank of Nova Scotia has been appointed by Goldcorp Inc. (NYSE:GG) to look into selling the Canadian gold producer’s operations of the Camino Rojo gold and silver project in Mexico. More...

  • Currently 0.00/5

Rating: 0.0/5 (0 votes)

Express Scripts to Include Harvoni in Hepatitis Cure Value Program The treatment cost will be reduced close to 50% David Dreman,Wallace Weitz,Chris Davis,Joel Greenb - Express Scripts To Include Harvoni In Hepatitis Cure Value Program
As announced by Express Scripts (NASDAQ:ESRX) through PR Newswire Dec. 12, the program that targets the treatment of patients affected with the hepatitis C virus, called “Hepatitis Cure Value Program,” will be upgraded with another product in January. More...

  • Currently 0.00/5

Rating: 0.0/5 (0 votes)

RBC Capital Updates Multiple Gold Stocks The Canadian firm releases new forecasts David Dreman - RBC Capital Updates Multiple Gold Stocks
Gold continues its downturn. More...

  • Currently 0.00/5

Rating: 0.0/5 (0 votes)

AbbVie's Imbruvica Has Favorable Response Rate Among Marginal Zone Lymphoma Patients Researchers observed a general response rate of 48% David Dreman,Joel Greenblatt - AbbVie's Imbruvica Has Favorable Response Rate Among Marginal Zone Lymphoma Patients
On Dec. 5, AbbVie Inc. (NYSE:ABBV) announced through PR Newswire the results regarding whether ibrutinib (Imbruvica), a type of chemotherapy drug for the treatment of patients suffering from relapsed / refractory marginal zone lymphoma (MZL), is effective and safe. More...

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.

Latest Guru Stock Picks


Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK